KRYS — Krystal Biotech, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1711279 ·
Last close
$363.28
Market Cap
$10.71B
52W High
$382.54
52W Low
$251.97
ADV30
552,767
Next earnings
2026-08-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 116,357,000 | 110,034,000 | 53,689,000 | 55,932,000 | 1,396,967,000 | 501,313,000 | 120,238,000 |
| Dec 2025 | 107,105,000 | 100,513,000 | 44,270,000 | 51,400,000 | 1,333,794,000 | 496,304,000 | 114,234,000 |
| Sep 2025 | 97,800,000 | 93,537,000 | 41,374,000 | 79,365,000 | 1,240,094,000 | 392,604,000 | 102,218,000 |
| Jun 2025 | 96,042,000 | 88,877,000 | 39,307,000 | 38,333,000 | 1,138,394,000 | 353,829,000 | 97,747,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$250,278,000
Investing CF
$-67,231,000
Financing CF
$10,712,000
CapEx
$-12,895,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$7.48
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$80,095,000
Inventory
$42,646,000
Receivables
$127,022,000
ST Investments
$322,092,000
EBIT TTM
$178,640,000
Pretax Income TTM
$207,315,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$417,304,000
EBITDA
$180,468,000
Free Cash Flow
$137,491,504
Enterprise Value
$10,000,355,328
Total Cash
$823,404,992
Total Debt
$9,112,000
Shares Out
29,479,756
Trailing EPS
$7.49
Book Value
$43.37
ROE
19.9%
ROA
9.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 389,130,000 | 161,295,000 | 204,831,000 | 1,333,794,000 | 114,234,000 | — | 200,865,000 |
| Dec 2024 | 290,515,000 | 103,248,000 | 89,159,000 | 1,055,838,000 | 109,458,000 | — | 123,420,000 |
| Dec 2023 | 50,699,000 | -97,117,000 | 10,932,000 | 818,355,000 | 39,714,000 | — | -88,804,000 |
| Dec 2022 | 0 | -120,196,000 | -139,975,000 | 558,450,000 | 36,219,000 | — | -100,569,000 |
TTM Snapshot
Revenues TTM
$92,397,000
NetIncome TTM
$62,488,000
OpCashFlow TTM
$0
Assets (Latest)
$1,055,838,000
Forward EPS
$9.87
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TECH | BIO-TECHNE Corp | $11.22B | $72.03 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $9.88B | $83.28 | — |
| KYMR | Kymera Therapeutics, Inc. | $8.66B | $105.25 | — |
| QGEN | QIAGEN N.V. | $8.62B | $41.81 | — |
| APGE | Apogee Therapeutics, Inc. | $8.28B | $134.20 | — |
News headlines (Yahoo Finance, 1h cache)
Krystal Biotech (KRYS) Could Be 40% Overvalued As KB801 News Tests Its Price
2026-07-30 08:07 · Yahoo
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?
2026-07-27 14:00 · Yahoo
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside Ahead
2026-07-24 21:20 · Yahoo
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
2026-07-23 21:00 · Yahoo
Krystal Biotech (KRYS) Soars 3.4%: Is Further Upside Left in the Stock?
2026-06-29 12:49 · Yahoo
The Brown Capital Management Small Company Fund Bets on Krystal Biotech (KRYS) for Its Resilient Revenue Stream
2026-06-24 13:55 · Yahoo
Stock Market Checklist Helps Uncover Winners In Hot Biotechs
2026-07-31 15:09 · Yahoo
Krystal Biotech (KRYS) Is Up 7.9% After S&P 400 Move And New KB801 Patent Filing Update
2026-07-30 00:15 · Yahoo
Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600
2026-07-20 21:42 · Yahoo
These Are 5 Of The Best Stocks To Buy Or Watch Now
2026-07-10 14:24 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.